Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
Public ClinicalTrials.gov record NCT00802867. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (HCP20/20/5/3DT-mIPV//PRP-T)
Study identification
- NCT ID
- NCT00802867
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Enrollment
- 989 participants
Conditions and interventions
Conditions
Interventions
- Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®) Biological
Biological
Eligibility (public fields only)
- Age range
- 4 Years to 6 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2004
- Primary completion
- May 31, 2005
- Completion
- Aug 31, 2005
- Last update posted
- Apr 13, 2016
2004 – 2005
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Jonesboro | Arkansas | 72401 | — |
| Not listed | Little Rock | Arkansas | 72205 | — |
| Not listed | Oakland | California | 94612 | — |
| Not listed | Torrance | California | 90502 | — |
| Not listed | Orlando | Florida | 32806 | — |
| Not listed | Atlanta | Georgia | 30322 | — |
| Not listed | Boston | Massachusetts | 02115 | — |
| Not listed | Woburn | Massachusetts | 01801 | — |
| Not listed | Omaha | Nebraska | 68131 | — |
| Not listed | Albany | New York | 12208 | — |
| Not listed | Rochester | New York | 14620 | — |
| Not listed | Chapel Hill | North Carolina | 27514 | — |
| Not listed | Sylva | North Carolina | 28779 | — |
| Not listed | Pittsburgh | Pennsylvania | 15241 | — |
| Not listed | Nashville | Tennessee | 37232 | — |
| Not listed | San Antonio | Texas | 78205 | — |
| Not listed | Layton | Utah | 84041 | — |
| Not listed | Vancouver | Washington | 98664 | — |
| Not listed | Marshfield | Wisconsin | 54449 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00802867, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 13, 2016 · Synced Jul 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00802867 live on ClinicalTrials.gov.